Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Astellas, Astrazeneca, Bayer, Kiniksa, Mallinckrodt, MC2, Merck, Redhill, Tetra, Tracon and Tricida.
An editorial yesterday in The New England Journal of Medicine (NEJM) marveled that “the world has now witnessed the compression of six years of work into six months,” and went on to ask the question that’s on everyone’s pandemic-wrenched mind: “Can the vaccine multiverse do it again, leading to a reality of a safe, efficacious COVID-19 vaccine for the most vulnerable in the next six [months]?”
Keeping you up to date on recent developments in orthopedics, including: Primitive stem cells point to new bone grafts for stubborn-to-heal fractures; Orthopedic surgeons issue guidelines on resuming elective surgery amid COVID-19 pandemic; Cardiac CT can double as osteoporosis test; Novel bone imaging approach provides insights into the progression of knee osteoarthritis.
RSS
